Home / Latest Reports / Rituximab Biosimilars Market

Rituximab Biosimilars Market by Type, Application, Key Players and Regions - Global Industry Analysis & Forecast to 2027

Published On : August 2022 Pages : 160 Category: Pharma & Healthcare Report Code : HC0817623

Request Sample Inquiry Before Buying Request for Customization Check Discount

The global Rituximab Biosimilars Market is valued at USD XX billion in 2021 and is projected to reach USD XX billion by the end of 2027, growing at a CAGR of XX% during the period 2022 to 2027.

The report exhibit detail coverage of Rituximab Biosimilars industry and market trends. The report also analyses present and past market values to forecast potential market through the forecast period between 2017-2022. This research study of Rituximab Biosimilars Market involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.

In addition, the report provides insight into main drivers, challenges, opportunities and risk of the market and strategies of suppliers. Key players are profiled as well. Overall, this report covers the historical situation, present status and the future prospects of the global Rituximab Biosimilars Market for 2017-2027.

Crystal Market Research envisions that the span of the Rituximab Biosimilars Market will develop amid the estimated time frame as the Compound Annual Growth Rate boosts significantly. The objective of the market research report is the current status of the market and in accordance classifies it into a few portions. The report takes into consideration the prime market players in every area from over the globe.

Our research study analyses the size of the global market of Rituximab Biosimilars in primary regions such as North America, South America, Middle East & Africa, Asia Pacific and Europe. It also classifies the Rituximab Biosimilars Market by key manufacturers, region, type and application. Furthermore, this study examines in the status of the market, market share, future trends, growth rate, competitive landscape, opportunities, market driving factors and restraints, and challenges.

To stay updated with the latest technology and functions of the industry, Crystal Market Research regularly performs interviews with several industry experts and visits for its expert research analysts. The data sources include but not limited to reports of company’s, international organizations and governments, MMI market surveys, and related industry news.

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2017 to 2027. This report has segmented the Rituximab Biosimilars Market on the basis of fabric, product, application, and region:

Competitive Analysis                    

The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

  • Celltrion
  • Cadila Pharmaceuticals
  • Teva
  • Biocad
  • Dr Reddy’s Laboratories
  • AryoGen Pharmed
  • Mylan
  • Amgen
  • Intas Biopharmaceuticals
  • Probiomed
  • Hetero Group
  • Innovent Biologics

By Type

  • 500mg
  • 100mg
  • Other

By Application

  • Retail Pharmacy
  • Hospital Pharmacy

By Region

  • North America (US, Canada,Mexico)
  • Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
  • South America (Brazil, Mexico, Columbia, Rest of South America)
  • Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Turkey, Rest of MEA)

Years considered for this report:
Historical Years: 2017-2021
Base Year: 2021
Estimated Year: 2022
Forecast Period: 2022-2027

Some of the key questions answered by the report are:

  • What was the market size in 2017 and forecast from 2022 to 2027?
  • What will be the industry market growth from 2017 to 2027?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Table of Contents

1.     Introduction

1.1.  Report Description

1.2.  Research Methodology

1.2.1.     Data Mining

1.2.2.     Market Modeling and Forecasting

1.2.3.     Data Validation

1.2.4.     Industry Analysis

2.     Market Dashboard

3.     Market Overview

3.1.  Introduction

3.1.1.     Market Definition

3.1.2.     Market Segmentation

3.2.  Market Dynamics

3.2.1.     Drivers

3.2.2.     Restraints

3.2.3.     Opportunities

3.2.4.     Challenges

4.     Rituximab Biosimilars Market, By Type

4.1.  Introduction

4.2.  Rituximab Biosimilars Market and Market Growth Rate By Type (2017-2022)

4.3.  500mg

4.3.1.     Global 500mg Market and Growth Rate (2017-2022)

4.4.  100mg

4.4.1.     Global 100mg Market and Growth Rate (2017-2022)

4.5.  Other

4.5.1.     Global Other Market and Growth Rate (2017-2022)

5.     Rituximab Biosimilars Market, By Application

5.1.  Introduction

5.2.  Rituximab Biosimilars Market and Market Growth Rate By Application (2017-2022)

5.3.  Retail Pharmacy

5.3.1.     Global Retail Pharmacy Market and Growth Rate (2017-2022)

5.4.  Hospital Pharmacy

5.4.1.     Global Hospital Pharmacy Market and Growth Rate (2017-2022)

6.     Rituximab Biosimilars Market, By Region

6.1.  Introduction

6.2.  Rituximab Biosimilars Market and Growth Rate By Regions

6.2  North America

6.2.1.     North America Rituximab Biosimilars Market and Growth Rate (2017-2022))

6.2.2.     North America Rituximab Biosimilars Market By Type (2017-2022)

6.2.3.     North America Rituximab Biosimilars Market By Application (2017-2022)

6.2.4.     North America Rituximab Biosimilars Market By Country (2017-2022)

6.2.5.     United States

6.2.5.1.United States Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.2.5.2.United States Rituximab Biosimilars Market By Type (2017-2022)

6.2.5.3.United States Rituximab Biosimilars Market By Application (2017-2022)

6.2.6.     Canada

6.2.6.1.Canada Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.2.6.2.Canada Rituximab Biosimilars Market By Type (2017-2022)

6.2.6.3.Canada Rituximab Biosimilars Market By Application (2017-2022)

6.3  Europe

6.3.1.     Europe Rituximab Biosimilars Market and Growth Rate (2017-2022))

6.3.2.     Europe Rituximab Biosimilars Market By Type (2017-2022)

6.3.3.     Europe Rituximab Biosimilars Market By Application (2017-2022)

6.3.4.     Europe Rituximab Biosimilars Market By Country (2017-2022)

6.3.5.     Germany

6.3.5.1.Germany Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.3.5.2.Germany Rituximab Biosimilars Market By Type (2017-2022)

6.3.5.3.Germany Rituximab Biosimilars Market By Application (2017-2022)

6.3.6.     France

6.3.6.1.France Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.3.6.2.France Rituximab Biosimilars Market By Type (2017-2022)

6.3.6.3.France Rituximab Biosimilars Market By Application (2017-2022)

6.3.7.     UK

6.3.7.1.UK Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.3.7.2.UK Rituximab Biosimilars Market By Type (2017-2022)

6.3.7.3.UK Rituximab Biosimilars Market By Application (2017-2022)

6.3.8.     Russia

6.3.8.1.Russia Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.3.8.2.Russia Rituximab Biosimilars Market By Type (2017-2022)

6.3.8.3.Russia Rituximab Biosimilars Market By Application (2017-2022)

6.3.9.     Italy

6.3.9.1.Italy Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.3.9.2.Italy Rituximab Biosimilars Market By Type (2017-2022)

6.3.9.3.Italy Rituximab Biosimilars Market By Application (2017-2022)

6.3.10.     Rest of Europe

6.3.10.1.Rest of Europe Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.3.10.2.Rest of Europe Rituximab Biosimilars Market By Type (2017-2022)

6.3.10.3.Rest of Europe Rituximab Biosimilars Market By Application (2017-2022)

6.4  Asia-Pacific

6.4.1.     Asia-Pacific Rituximab Biosimilars Market and Growth Rate (2017-2022))

6.4.2.     Asia-Pacific Rituximab Biosimilars Market By Type (2017-2022)

6.4.3.     Asia-Pacific Rituximab Biosimilars Market By Application (2017-2022)

6.4.4.     Asia-Pacific Rituximab Biosimilars Market By Country (2017-2022)

6.4.5.     China

6.4.5.1.China Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.4.5.2.China Rituximab Biosimilars Market By Type (2017-2022)

6.4.5.3.China Rituximab Biosimilars Market By Application (2017-2022)

6.4.6.     Japan

6.4.6.1.Japan Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.4.6.2.Japan Rituximab Biosimilars Market By Type (2017-2022)

6.4.6.3.Japan Rituximab Biosimilars Market By Application (2017-2022)

6.4.7.     Korea

6.4.7.1.Korea Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.4.7.2.Korea Rituximab Biosimilars Market By Type (2017-2022)

6.4.7.3.Korea Rituximab Biosimilars Market By Application (2017-2022)

6.4.8.     India

6.4.8.1.India Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.4.8.2.India Rituximab Biosimilars Market By Type (2017-2022)

6.4.8.3.India Rituximab Biosimilars Market By Application (2017-2022)

6.4.9.     Southeast Asia

6.4.9.1.Southeast Asia Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.4.9.2.Southeast Asia Rituximab Biosimilars Market By Type (2017-2022)

6.4.9.3.Southeast Asia Rituximab Biosimilars Market By Application (2017-2022)

6.4.10.     Rest of Asia-Pacific

6.4.10.1.Rest of Asia-Pacific Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.4.10.2.Rest of Asia-Pacific Rituximab Biosimilars Market By Type (2017-2022)

6.4.10.3.Rest of Asia-Pacific Rituximab Biosimilars Market By Application (2017-2022)

6.5  South America

6.5.1.     South America Rituximab Biosimilars Market and Growth Rate (2017-2022))

6.5.2.     South America Rituximab Biosimilars Market By Type (2017-2022)

6.5.3.     South America Rituximab Biosimilars Market By Application (2017-2022)

6.5.4.     South America Rituximab Biosimilars Market By Country (2017-2022)

6.5.5.     Brazil

6.5.5.1.Brazil Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.5.5.2.Brazil Rituximab Biosimilars Market By Type (2017-2022)

6.5.5.3.Brazil Rituximab Biosimilars Market By Application (2017-2022)

6.5.6.     Mexico

6.5.6.1.Mexico Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.5.6.2.Mexico Rituximab Biosimilars Market By Type (2017-2022)

6.5.6.3.Mexico Rituximab Biosimilars Market By Application (2017-2022)

6.5.7.     Columbia

6.5.7.1.Columbia Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.5.7.2.Columbia Rituximab Biosimilars Market By Type (2017-2022)

6.5.7.3.Columbia Rituximab Biosimilars Market By Application (2017-2022)

6.5.8.     Rest of South America

6.5.8.1.Rest of South America Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.5.8.2.Rest of South America Rituximab Biosimilars Market By Type (2017-2022)

6.5.8.3.Rest of South America Rituximab Biosimilars Market By Application (2017-2022)

6.6  Middle East and Africa

6.6.1.     Middle East and Africa Rituximab Biosimilars Market and Growth Rate (2017-2022))

6.6.2.     Middle East and Africa Rituximab Biosimilars Market By Type (2017-2022)

6.6.3.     Middle East and Africa Rituximab Biosimilars Market By Application (2017-2022)

6.6.4.     Middle East and Africa Rituximab Biosimilars Market By Country (2017-2022)

6.6.5.     Saudi Arabia

6.6.5.1.Saudi Arabia Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.6.5.2.Saudi Arabia Rituximab Biosimilars Market By Type (2017-2022)

6.6.5.3.Saudi Arabia Rituximab Biosimilars Market By Application (2017-2022)

6.6.6.     United Arab Emirates

6.6.6.1.United Arab Emirates Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.6.6.2.United Arab Emirates Rituximab Biosimilars Market By Type (2017-2022)

6.6.6.3.United Arab Emirates Rituximab Biosimilars Market By Application (2017-2022)

6.6.7.     South Africa

6.6.7.1.South Africa Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.6.7.2.South Africa Rituximab Biosimilars Market By Type (2017-2022)

6.6.7.3.South Africa Rituximab Biosimilars Market By Application (2017-2022)

6.6.8.     Rest of Middle East and Africa

6.6.8.1.Rest of Middle East and Africa Rituximab Biosimilars Market and Growth Rate (2017-2022)

6.6.8.2.Rest of Middle East and Africa Rituximab Biosimilars Market By Type (2017-2022)

6.6.8.3.Rest of Middle East and Africa Rituximab Biosimilars Market By Application (2017-2022)

7.     Company Profiles

7.1.  Celltrion

7.1.1.     Business Overview

7.1.2.     Service Portfolio

7.1.3.     Strategic Developments

7.1.4.     Financial Overview

7.2.  Cadila Pharmaceuticals

7.2.1.     Business Overview

7.2.2.     Service Portfolio

7.2.3.     Strategic Developments

7.2.4.     Financial Overview

7.3.  Teva

7.3.1.     Business Overview

7.3.2.     Service Portfolio

7.3.3.     Strategic Developments

7.3.4.     Financial Overview

7.4.  Biocad

7.4.1.     Business Overview

7.4.2.     Service Portfolio

7.4.3.     Strategic Developments

7.4.4.     Financial Overview

7.5.  Dr Reddy’s Laboratories

7.5.1.     Business Overview

7.5.2.     Service Portfolio

7.5.3.     Strategic Developments

7.5.4.     Financial Overview

7.6.  AryoGen Pharmed

7.6.1.     Business Overview

7.6.2.     Service Portfolio

7.6.3.     Strategic Developments

7.6.4.     Financial Overview

7.7.  Mylan

7.7.1.     Business Overview

7.7.2.     Service Portfolio

7.7.3.     Strategic Developments

7.7.4.     Financial Overview

7.8.  Amgen

7.8.1.     Business Overview

7.8.2.     Service Portfolio

7.8.3.     Strategic Developments

7.8.4.     Financial Overview

7.9.  Intas Biopharmaceuticals

7.9.1.     Business Overview

7.9.2.     Service Portfolio

7.9.3.     Strategic Developments

7.9.4.     Financial Overview

7.10.  Probiomed

7.10.1.     Business Overview

7.10.2.     Service Portfolio

7.10.3.     Strategic Developments

7.10.4.     Financial Overview

7.11.  Hetero Group

7.11.1.     Business Overview

7.11.2.     Service Portfolio

7.11.3.     Strategic Developments

7.11.4.     Financial Overview

7.12.  Innovent Biologics

7.12.1.     Business Overview

7.12.2.     Service Portfolio

7.12.3.     Strategic Developments

7.12.4.     Financial Overview

Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources
  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources
  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)
  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*
*
*